The choice of miR-32-5p was informed by evidence of context-specific oncogenic activity across various cancer types—most notably its regulation of BMP5 and PTEN in colorectal and prostate cancers (e.g., Scaravilli et al. 2022) and its targeting of the tumor suppressor FBXW7 in breast cancer, Xia et al. 2017 [47]. This evidence concerns the gene BMP5 and breast cancer.